Neuropsychiatric symptoms of fragile X syndrome: Pathophysiology and pharmacotherapy

CNS Drugs

Volumn 18, Issue 11, 2004, Pages 687-703

  Tsiouris, John A ^a,b   Brown, W Ted ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b IBR George A Jervis Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CLONIDINE; FLUOXETINE; FOLIC ACID; FRAGILE X MENTAL RETARDATION PROTEIN; GUANFACINE; IMIPRAMINE; LEVACECARNINE; METHYLPHENIDATE; MOOD STABILIZER; NADOLOL; OLANZAPINE; PEMOLINE; PINDOLOL; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGGRESSION; ANXIETY DISORDER; AROUSAL; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; BEHAVIOR; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BRAIN DEVELOPMENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEPRESSION; FAMILY HISTORY; FRAGILE X SYNDROME; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERACTIVITY; HYPOTENSION; IMPULSE CONTROL DISORDER; IRRITABILITY; LIVER TOXICITY; MENTAL DISEASE; MOOD DISORDER; MOSAICISM; NEUROPSYCHIATRY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SEX DIFFERENCE; SOCIAL PHOBIA; SOMNOLENCE; SYMPTOM; TEMPERAMENT; TIC; X CHROMOSOME;

ANIMALS; BEHAVIORAL SYMPTOMS; FAMILY HEALTH; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MENTAL DISORDERS; MUTATION; NERVE TISSUE PROTEINS; PSYCHOTROPIC DRUGS; RNA-BINDING PROTEINS;

EID: 4544306641     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418110-00001     Document Type: Review

References (120)

1. O'Donnell WT, Warren ST. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 2002; 25: 315-38
2. Brown WT. The molecular biology of the fragile X mutation. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment and research. 3rd ed. Baltimore (MD): Johns Hopkins University Press, 2002: 110-35
3. Nolin SL, Lewis French III A, Ye LL, et al. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 1996; 59: 1252-61
4. Brown WT, Houck Jr GE, Jeziorowska A, et al. Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. JAMA 1993; 270 (13): 1569-75
5. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Cronister A. editors. Fragile X syndrome: diagnosis, treatment and research. 3rd ed. Baltimore (MD): Johns Hopkins University Press, 2002: 3-109
6. Sobesky WE, Hull CE, Hagerman RJ. Symptoms of schizotypal personality disorder in fragile X women. J Am Acad Child Adolesc Psychiatry 1994; 33 (2): 247-55
7. Sobesky WE, Pennington BF, Porter D, et al. Emotional and neurocognitive deficits in fragile X. Am J Med Genet 1994; 51 (4): 378-85
8. Franke P, Maier W, Hautzinger M, et al. Fragile-X carrier females: evidence for a distinct psychopathological phenotype? Am J Med Genet 1996; 64 (2): 334-9
9. Franke P, Leboyer M, Gansicke M, et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res 1998; 80 (2): 113-27
10. Lachiewicz AM, Dawson DV. Behavior problems of young girls with fragile X syndrome: factor scores on the Conners' Parent's Questionnaire. Am J Med Genet 1994; 51 (4): 364-9
11. Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics 1993; 91 (2): 321-9
12. Sobesky WE, Taylor AK, Pennington BF, et al. Molecular/clinical correlations in females with fragile X. Am J Med Genet 1996; 64 (2): 340-5
13. Riddle JE, Cheema A, Sobesky WE, et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard 1998; 102 (6): 590-601
14. Abrams MT, Reiss AL, Freund LS, et al. Molecular-neurobehavioral associations in females with the fragile X full mutation. Am J Med Genet 1994; 51 (4): 317-27
15. Rousseau F, Heitz D, Tarleton J, et al. A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases. Am J Hum Genet 1994; 55 (2): 225-37
16. de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Med Genet 1996; 58: 1025-32
17. Mazzocco MM, Pennington BF, Hagerman RJ. The neurocognitive phenotype of female carriers of fragile X: additional evidence for specificity. J Dev Behav Pediatr 1993; 14 (5): 328-35
18. Bennetto L, Pennington BF. Neuropsychology. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment and research. 3rd ed. Baltimore (MD): Johns Hopkins University Press, 2002: 206-48
19. Merenstein SA, Sobesky WE, Taylor AK, et al. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996; 64 (2): 388-94
20. Hagerman RJ, Hull CE, Safanda JF, et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet 1994; 51 (4): 298-308
21. Baumgardner TL, Green KE, Reiss AL. A behavioral neurogenetics approach to developmental disabilities: gene-brain-behavior associations. Curr Opin Neurol 1994; 7 (2): 172-8
22. Lachiewicz AM, Spiridigliozzi GA, Gullion CM, et al. Aberrant behaviors of young boys with fragile X syndrome. Am J Ment Retard 1994; 98 (5): 567-79
23. Kerby DS, Dawson BL. Autistic features, personality, and adaptive behavior in males with the fragile X syndrome and no autism. Am J Ment Retard 1994; 98 (4): 455-62
24. Einfeld S, Tonge B, Turner G. Longitudinal course of behavioral and emotional problems in fragile X syndrome. Am J Med Genet 1999; 87 (5): 436-9
25. Carey WB. The difficult child. Pediatr Rev 1986; 8 (2): 39-45
26. Thomas A, Chess S, Birch H, et al. Temperament and personality. In: Kohnstamm G, Bates J, Rothbart M, editors. Temperament in childhood. New York: John Wiley, 1989: 249-62
27. Carey WB, Jablow MM. Understanding your child's temperament. New York: Macmillan, 1997
28. Hatton DD, Bailey Jr DB, Hargett-Beck MQ, et al. Behavioral style of young boys with fragile X syndrome. Dev Med Child Neurol 1999; 41 (9): 625-32
29. McDevitt SC, Carey WB. The measurement of temperament in 3-7 year old children. J Child Psychol Psychiatry 1978; 19 (3): 245-53
30. Thomas A, Chess S, Birch H, et al. Behavioral individuality in early childhood. New York: University Press, 1963
31. Carey W, McDevitt S. Coping with children's temperament: a guide for professionals. New York: Basic Books, 1995
32. Carey WB, McDevitt SC, Baker D. Differentiating minimal brain dysfunction and temperament. Dev Med Child Neurol 1979; 21 (6): 765-72
33. DiLavore P. Maternal ratings of temperament in children with autism and children with Down syndrome [unpublished dissertation]. Chapel Hill (NC): University of North Carolina at Chapel Hill, 1991
34. Gunn P, Berry P. The temperament of Down's syndrome toddlers and their siblings. J Child Psychol Psychiatry 1985; 26 (6): 973-9
35. Carey WB. Teaching parents about infant temperament. Pediatrics 1998; 102 (5 Suppl. E): 1311-6
36. Rothbart M, Bates J. Temperament. In: Damon W, Eisenberg N, editors. Handbook of child psychology: social, emotional, and personality development. New York (NY): John Wiley, 1998
37. Wolff PH, Gardner J, Paccla J, et al. The greeting behavior of fragile X males. Am J Ment Retard 1989; 93 (4): 406-11
38. Scharfenaker S, O'Connor R, Stackhouse T, et al. An integrated approach to intervention. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment and research. 3rd ed. Baltimore (MD): The Johns Hopkins University Press, 2002; 363: 427
39. Cohen IL. A theoretical analysis of the role of hyperarousal in the learning and behavior of fragile X males. Ment Retard Dev Disabil Res Rev 1995; 1: 286-91
40. Wells A, Clark DM, Salkovskis P, et al. Social phobia: the role of in-situation safety behaviors in maintaining anxiety and negative beliefs. Behav Ther 1995; 26: 153-61
41. Belser RC, Sudhalter V. Arousal difficulties in males with Fragile X syndrome: a preliminary report. Dev Brain Dysfunct 1995; 8: 270-9
42. Miller LJ, McIntosh DN, McGrath J, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet 1999; 83 (4): 268-79
43. Boucsein W. Electrodermal activity. New York: Plenum Press, 1992
44. van Engeland H. The electrodermal orienting response to auditive stimuli in autistic children, normal children, mentally retarded children, and child psychiatric patients. J Autism Dev Disord 1984; 14 (3): 261-79
45. Hagerman RJ, Miller LJ, McGrath-Clarke J, et al. Influence of stimulants on electrodermal studies in Fragile X syndrome. Microsc Res Tech 2002; 57 (3): 168-73
46. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 1988; 30 (1-2): 377-92
47. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985; 24 (5): 617-29
48. Abitbol M, Menini C, Delezoide A, et al. Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet 1993; 4 (2): 147-53
49. Beardslee WR, Versage EM, Gladstone TRG. Children of affectively ill parents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1998; 37: 1134-41
50. Smalley SL, McCracken J, Tanguay P. Autism, affective disorders, and social phobia. Am J Med Genet 1995; 60: 19-26
51. Mazzocco MMM, Baumgardner T, Freund LS, et al. Social functioning among girls with fragile X or Turner syndrome and their sisters. J Autism and Dev Disord 1998; 28 (6): 509-17
52. Hessl D, Dyer-Friedman J, Glaser B, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics 2001; 108(5): 1-9
53. Tsiouris JA, Cohen IL, Patti PJ, et al. Treatment of the previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. J Clin Psychiatry 2003; 64 (9): 1081-90
54. Howard-Peebles PN, Stoddard GR, Miss MG. Familial X-linked mental retardation, verbal disability and marker X chromosome. Am J Hum Genet 1979; 31: 214-22
55. Spinelli M, de Oliveira Rocha AC, Giacheti CM, et al. Word-finding difficulties, verbal paraphasias, and verbal dyspraxia in ten individuals with fragile X syndrome. Am J Med Genet 1995; 60: 39-43
56. Sudhalter V, Scarborough HS, Cohen IL. Syntactic delay and pragmatic deviance in the language of fragile X males. Am J Med Genet 1991; 38: 493-7
57. Sudhalter V, Cohen IL, Silverman W, et al. Conversational analyses of males with fragile X, Down syndrome and autism: comparison of the emergence of deviant language. Am J Ment Retard 1990; 94: 431-41
58. Sudhalter V, Belser RC. Conversational characteristics of children with fragile X syndrome: tangential language. Am J Ment Retard 2001; 106(5): 389-00
59. Hagerman RJ, Jackson AW, Levitas A, et al. An analysis of autism in 50 males with fragile X syndrome. Am J Med Genet 1986; 23: 359-70
60. Turk J, Cornish K. Face recognition and emotion perception in boys with fragile-X syndrome. J Intellect Disabil Res 1998; 42 (6): 490-9
61. Hobson RP. The autistic child's appraisal of expressions of emotion: a further study. J Child Psychol Psychiatry 1986; 27: 671-80
62. Davies S, Bishop D, Manstead SR, et al. Face perception in children with autism and Asperger's syndrome. J Child Psychol Psychiatry 1994; 35: 1033-57
63. Hatton DD, Hooper SR, Bailey DB, et al. Problem behavior in boys with fragile X syndrome. Am J Med Genet 2002; 108: 105-16
64. Cohen IL, Sudhalter V, Pfadt A, et al. Why are autism and the fragile X syndrome associated? Am J Hum Genet 1991; 48: 195-202
65. Brown WT, Jenkins EC, Friedman E, et al. Autism is associated with the fragile X syndrome. J Autism Dev Disabilities 1982; 12: 303-7
66. Brown WT, Jenkins EC, Cohen IL, et al. Fragile X and autism: a multicenter survey. Am J Med Genet 1986; 23: 341-52
67. Dykens EM, Volkmar FR. Medical conditions associated with autism. In: Cohen DJ, Volkmar FR. editors. Handbook of autism and pervasive developmental disorder. 2nd ed. New York: J. Wiley, 1997: 388-407
68. Bailey A, Bolton P, Butler L, et al. Prevalence of the fragile X anomaly amoungst autistic twins and singletons. J Child Psychol Psychiatry 1993; 34: 673-88
69. Bailey DB, Hatton DD, Skinner M, et al. Autistic behavior, FMR1 protein and developmental trajectories in young males with fragile X syndrome. J Autism Dev Disord 2001; 31: 165-74
70. Lamb JA, Parr JR, Bailey AJ, et al. Autism: in search of susceptibility genes. Neuromolecular Med 2002; 2: 11-28
71. Feinstein C, Reiss AL. Autism: the point of view from fragile X studies. J Autism Dev Disord 1998; 28: 393-405
72. Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 2001 Dec; 22 (6): 409-17
73. Cohen IL, Liu X, Schutz C, et al. Association of autism severity with an MAOA functional polymorphism. Clin Genet 2003; 64: 190-7
74. Amaria RN, Billeisen LL, Hagerman RJ, Medication use in fragile X syndrome. Ment Health Aspects Dev Disabil 2001; 4: 143-7
75. Hagerman RJ, Fulton MJ, Leaman A, et al. A survey of fluoxetine therapy in fragile X syndrome. Dev Brain Dysfunct 1994; 7: 155-64
76. Hagerman RJ, Hills J, Scharfenaker S, et al. Fragile X syndrome and selective mutism. Am J Med Genet 1999; 83 (4): 313-7
77. Rojahn J, Borthwick-Duffy SA, Jacobson JW. The association between psychiatric diagnoses and severe behavior problems in mental retardation. Ann Clin Psychiatry 1993; 5: 163-70
78. Tsiouris JA, Mann R, Patti PJ, et al. Challenging behaviours should not be considered as depressive equivalents in individuals with intellectual disability. J Intellect Disabil Res 2003 Jan; 47 (1): 14-21
79. Sutherland GR. Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 1977; 197 (4300): 265-6
80. Greenblatt JM, Huffman LC, Reiss AL. Folic acid in neurodevelopment and child psychiatry. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 647-60
81. Lejeune J. Is the fragile X syndrome amenable to treatment? Lancet 1982; I (8266): 273-4
82. Lejeune J, Rethore MO, de Blois MC, et al. Trial of folic acid treatment in fragile X syndrome [in French]. Ann Genet 1984; 27 (4): 230-2
83. Hagerman RJ, Jackson AW, Levitas A, et al. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet 1986; 23: 241-62
84. Hagerman RJ. Medical follow-up and pharmacotherapy. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment and research. 3rd ed. Baltimore (MD): Johns Hopkins University Press, 2002: 287-338
85. Torrioli MG, Vernacotola S, Mariotti P, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 1999; 87 (4): 366-8
86. Aman MG, Singh NN. Methylphenidate in severely retarded residents and the clinical significance of stereotypic behavior. Appl Res Ment Retard 1982; 3 (4): 345-58
87. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (7): 776-84
88. Hilton DK, Martin CA, Heffron WM, et al. Imipramine treatment of ADHD in a fragile X child. J Am Acad Child Adolesc Psychiatry 1991; 30: 831-4
89. Hellings JC, Gaffney GR. A trigger for Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31 (2): 371-2
90. Dunner KL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry 1998; 59: 366-74
91. Berry-Kravis E. Clinical trial of a new medication in adults with fragile X [online]. Available from URL: http://www.fraxa.org/html/r_BerryKravis.htm [Accessed 2004 Jul 30]
92. Steiner H, Saxena K, Chang K. Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectrums 2003; 8 (4): 298-308
93. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; Jul; 27(7): 370-7.
94. Coccaro EF, Harvey PD, Kupsaw-Lawrence E, et al. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 1991; 3 (2): S44-51
95. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989; 8: 52-62
96. Hagerman RJ, Bregman JD, Tirosh E. Clonidine. In: Reis S, Aman MG, editors. Psychotropic medication and developmental disabilities: the international consensus handbook. Columbus (OH): Ohio State University Nisonger Center, 1998: 259-69
97. Hagerman RJ, Riddle JE, Roberts LS, et al. A survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct 1995; 8: 336-44
98. Tyrer PJ, Lader MH. Response to propranolol and diazepam in somatic and psychic anxiety. BMJ 1974; 2 (909): 14-6
99. Williams EM, Campbell TJ. The effects of nadolol on various cardiac tissues in normoxia, and on atrial muscle in simulated ischaemia. Eur J Pharmacol 1982; 83 (3-4): 161-9
100. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 1986; 47 (8): 423-6
101. Reudrich SL, Crush L, Wilson J. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard 1990; 95: 110-9
102. Cohen IL, Tsiouris JA, Pfadt A. Effects of long-acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: a double-blind, placebo-controlled study. J Clin Psychopharmacol 1991; 11 (6): 398-9
103. Hagerman RJ. Medical follow-up and pharmacotherapy. In: Hagerman RJ, Cronister A, editors. Fragile X syndrome: diagnosis, treatment, and research. 2nd ed. Baltimore (MD): Johns Hopkins University Press, 1996: 283-331
104. Tsiouris JA. Diagnosis of depression in people with severe/profound intellectual disability. J Intellect Disabil Res 2001; 45 (Pt 2): 115-20
105. Szymanski LS, King B, Goldberg B, et al. Diagnosis of mental disorders in people with mental retardation. In: Reiss S, Aman MG, editors. Psychotropic medications and developmental disabilities: the international consensus handbook. Columbus (OH): Ohio State University Nisonger Center, 1998: 3-17
106. Backes M, Gene B, Schreck J, et al. Cognitive and behavioral profile of fragile X boys: correlations to molecular data. Am J Med Genet 2000; 95 (2): 150-6
107. Reilly JG, Avis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-52
108. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002 Nov; 325: 1070-2
109. Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry 2001; 6 (1): 13-34
110. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992; 15: 353-75
111. Paradee W, Melikian HE, Rasmussen DL, et al. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 1999; 94(1): 185-92
112. Tamm L, Menon V, Johnston CK, et al. fMRI study of cognitive interference processing in females with fragile X syndrome. J Cogn Neurosci 2002 Feb 15; 14 (2): 160-71
113. Yang TT, Menon V, Eliez S, et al. Amygdalar activation associated with positive and negative facial expressions. Neuroreport 2002 Oct 7; 13 (14): 1737-41
114. Musumeci SA, Bosco P, Calabrese G, et al. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 2000; 41 (1): 19-23
115. Huber KM, Gallagher SM, Warren ST, et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002; 99 (11): 7746-50
116. Kent JM, Mathew SJ, German JM. Molecular targets in the treatment of anxiety. Biol Psychiatry 2002; 52: 1008-30
117. Lainhart JE. Psychiatric problems in individuals with autism, their parents and siblings. Int Rev Psychiatry 1999; 11: 278-98
118. McDougle CJ, Posey DJ. Autistic and other pervasive developmental disorders. In: Martin A, Scahill L, Charney DS, et al., editors. Pediatric psychopharmacology: principles and practice. New York: Oxford University Press, 2002
119. Aman MG, Langworthy KS. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord 2000; 30 (5): 451-9
120. King BH. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord 2000; 30 (5): 439-45